Review
The use of laboratory-developed tests (LDT) was unfamiliar to me before I started to create this molecular atmosphere within our microbiology department at the System Laboratory of OSF Saint Francis Medical Center. My experience with diagnostic testing had usually included using a kit containing a product insert with step-by-step instructions on how to perform the test in question. However, the herpes simplex virus (HSV) assay and Bordetella pertussis/ parapertussis (hereafter, Bordetella) test performed via real-time PCR needed to be developed, validated, and verified; protocols needed to be written based on the steps that we found to be successful.
LDTs, also known as home-brew tests, are developed inhouse and used for research or diagnostic purposes. LDTs are not frequently encountered in certified clinical laboratories; they are more commonly found in research-based facilities. This type of assay has not been approved by the United States Food and Drug Administration (FDA), so no commercial kits are available. Laboratories that create home-brew assays can make the reagents themselves or buy reagents from outside vendors and develop their own protocol for testing. The validation and verification process for LDTs can be extensive and costly. Many facilities do not have the knowledge base or the time to develop such assays.
As I mentioned in a previous installment of this series, we had created our molecular lab by defining 3 distinct areas for testing. We also had developed regulations on cleaning and appropriate usage of personal protective equipment for each of the designated areas. Since the layout of the molecular area had begun to take shape and we already had our instrumentation and required materials, the next course of action was to create a protocol for HSV and Bordetella testing, respectively.
We investigated each of the elements and created protocols for both assays based on evidence we gathered from the manufacturers of all supplies and equipment used, other facilities performing similar testing, the Clinical Microbiology Procedures Handbook published by the American Society for Microbiology (ASM), a variety of published online literature, and information provided by the Clinical and Laboratory Standards Institute (CLSI). We made our best attempt to maintain compliance with the specifications of the Clinical Laboratory Improvement Amendment (CLIA) and those of the College of American Pathologists (CAP). Using samples with known results, we performed trial runs of both assays to ensure that we could duplicate results. We were able to evaluate all aspects of each protocol and to optimize the runs while eliminating room for error.
The basic steps of HSV testing included automated extraction (using the BioRobot EZ1 [Qiagen NV, Venlo, Netherlands]), amplification and detection (using the SmartCycler [Cepheid, Sunnyvale, CA]), and interpretation and reporting of results. Bordetella testing, however, did not include a separate extraction step. We decided to try a protocol that incorporated the extraction in the first few e60 Lab Medicine Spring 2014 | Volume 45, Number 2 www.labmedicine.com Review heating cycles of the SmartCycler so that extraction, amplification, and detection all occurred in the same closed system. For each assay we needed to consider many detailed elements, including reagent storage, specimen collection and storage, materials required, quality control, testing procedure, results and reporting, reference ranges, performance characteristics, and any precautions specifically related to that assay.
We performed validation and verification of the results of each assay simultaneously in each of the trial runs. This process is more time consuming for a LDT than for an FDA-approved assay. LDT results should be validated and verified by the laboratory that is developing the protocol for the test in question (FDA-approved test results have already been validated); only verification of the test results is required by the laboratory. Also, the evaluation process for an LDT and the extent of its completion were strongly in question, because there was not a lot of hard evidence to support what we should do. When I started the evaluation of HSV testing via PCR, I referred to guidelines from an online article published in 2006 in the journal Clinical Microbiology Reviews (published by the American Society for Microbiology). Since then, increased demand for LDTs has allowed CLSI and CAP to become more involved in developing guidelines for laboratories; these guidelines have evolved to become more descriptive and user friendly. Table 1 presents a set of suggestive guidelines for validation and verification of qualitative LDTs.
The evaluations of tests for HSV and Bordetella varied somewhat in approach, requirements for validation and verification, and acceptable limits , due to the time lapse between the HSV-and the Bordetella test evaluations. Recommendations from CLSI, other facilities, online literature, and our own pathologists on how to perform each evaluation were different. By the time we started the Bordetella-test evaluation, our knowledge was much stronger, and we had a better handle on the concept of validating and verifying LDTs. We began performing HSV testing on patients in late 2007 and we started Bordetella testing in 2010. Both kinds of 
